Most material SEC filings — August 11, 2026

RYTHM, Inc. amended its secured convertible notes and warrant agreements with RSLGH, LLC and Vision Management Services, LLC, effective October 10, 2026. The amendment removes all beneficial ownership limitations (49.99% caps) that previously restricted exercise/conversion of: the November 2024 Note ($10M, converted to 3.22M warrant shares in Nov 2025), the May 2025 Note ($27M), the August 2025 Note ($45M), and approximately 9.5M warrant shares issued as interest and service payments. RSLGH is the sole Required Holder of all notes and warrants.

BioXcel Therapeutics amended its credit agreement with Oaktree Fund Administration (lenders) effective immediately. Key changes: (1) New transaction milestone requiring the company to enter definitive agreements by August 21, 2026, for either full debt repayment in cash or an alternative capital solution acceptable to majority lenders; (2) Minimum liquidity requirements reduced from $25M initially to $3M by August 10, 2026; (3) Added three commercial tort claims to collateral (disputes with Cognitive Research, Caitlin Meyer, and Segal Institute). The covenant relaxation signals lenders are accommodating deteriorating liquidity while imposing a hard deadline for a material capital event.

Venture Global reported Q2 2026 revenue of $4.6 billion (48% YoY increase) and net income of $1.3 billion (266% YoY increase). The company raised full-year 2026 Consolidated Adjusted EBITDA guidance to $8.7–9.1 billion from $8.2–8.5 billion, reflecting strong operational performance, 2+ MTPA of new LNG offtake agreements (Atlantic-SEE increased to 1.0 MTPA, new EnBW 0.82 MTPA deal, plus TotalEnergies 0.85 MTPA and Vitol increase to 1.7 MTPA), and refinancings ($2.25B, $1.75B, $1.5B, and $750M debt facilities) generating >$100M in annual cost savings. Dividend increased 122% to $0.04/share; Calcasieu Pass shipped 37 cargos in Q2 despite major maintenance; Plaquemines Phase 1 COD reaffirmed for Q4 2026.

Shattuck Labs completed a $86.2M underwritten public offering and realized $57.1M from warrant exercises (July 2026), boosting cash/investments to $208.3M as of June 30, 2026 versus $50.5M a year prior. The company reports positive Phase 1 data for lead candidate SL-325 (DR3 blocking antibody) showing favorable safety, best-in-mechanism immunogenicity (3.7% antidrug antibodies), and durable blockade supporting quarterly dosing; Phase 2b trial (RECEPTIVE-CD1) in Crohn's disease initiates Q3 2026 with data expected H1 2028. SL-846 (DR3 × IL-23R bispecific) enters Phase 1 in 2027. Runway extends to 2029.

IES Holdings, Inc. (Buyer) agreed to acquire all outstanding shares of DBM Global, Inc. (Company) from parent Innovate Corp. and DBM Global Intermediate Holdco Inc. (Seller) via merger. Consideration consists of Stock Consideration (shares of Buyer Common Stock, amount not specified in excerpt) plus Seller Cash Consideration (amount not specified in excerpt), subject to purchase price adjustment based on closing working capital, cash, and indebtedness. Transaction dated August 7, 2026; Closing contingent on regulatory approvals (HSR, antitrust) and other standard conditions. Agreement includes 338(h)(10) tax elections and $35M tax-related payment to Seller.

On April 30, 2026, Broadwind sold its Abilene, Texas wind fabrication facility to IES Infrastructure for up to $19.5M, completing a strategic exit from wind tower manufacturing. Q2 2026 continuing operations (excluding divested wind/fabrication): revenue $24.3M (+67% YoY), Adjusted EBITDA $1.6M vs. -$1.1M YoY, loss from operations -$0.7M vs. -$3.0M YoY. Orders surged 68% YoY to $35.2M; combined Industrial Solutions and Gearing backlog grew 93% YoY. Cash position strengthened to $31.3M (net of minimum availability) with $6.3M total debt.

Harvard Bioscience (market cap ~$18.2M) completed a $40M debt refinancing with BroadOak Capital Partners consisting of $10M Term Loan A, $22.5M Term Loan B (converts at $10/share), and $7.5M Term Loan C. The refinancing extends maturity to December 2029, reduces annual debt service by $3M, and includes BroadOak board seat and 200K warrant grant. Company appointed new CEO John Duke (July 2025) and permanent CFO Mark Frost (March 2026), and announced Project Viking: consolidating Holliston, MA plant by Q1 2027, targeting $3M adjusted EBITDA improvement in 2027 and $4M ongoing. FY26 guidance raised to 3-5% revenue growth; adjusted EBITDA margin guided 57-59%.

Daniel Vitt's employment terminated August 7, 2026, with severance of ~$946k (base salary for 16.5 months plus 75% of 2026 bonus = $670k lump sum + $276.4k bonus + €18k/month healthcare for 18 months). He transitions to unpaid Founder/Chair of Scientific Advisory Board role with €15k/month consulting agreement (12 months, ≤15 hrs/month). Non-compete and IP restrictions imposed. Simultaneously, Immunic appointed Erik Lundgren as CEO (May 22, 2026), Michael Panzara as Chief Medical Officer (April 24, 2026), Michael Bonney as Board Chair (May 16, 2026), and Elena Ridloff to Board (August 6, 2026). Company has €155.1M cash; Q2 2026 net loss was $34.1M.

CalciMedica completed a private placement financing of approximately $49M (with ~$15M upfront) on June 24, 2026, to advance its pulmonary hypertension program including Auxora Phase 1b trial in PAH and CM5480 IND submission, both anticipated mid-2027. The company also achieved FDA alignment on Phase 2b acute pancreatitis trial design (primary endpoint: reduction in new-onset severe respiratory failure). Cash position: $18.6M as of June 30, 2026; net loss H1 2026: $2.7M ($0.16/share); common shares outstanding increased to 30.7M from 15.4M (99% dilution from capital raise).

Aura Biosciences executed a CEO transition on April 30, 2026: founder Elisabet de los Pinos terminated as CEO and transitioned to a 6-month consulting role with accelerated equity vesting; Natalie Holles hired as new CEO with $700k base salary, 55% bonus target, and ~2.5% equity grant (1.33M options + 367k RSUs) plus 0.5% performance-based RSUs. Simultaneously, the company repurchased up to 6.92M shares (from its $321M market cap) from investor Matrix Capital at the net public offering price, financed by a registered equity offering. The company also increased authorized common shares from 150M to 500M and extended option exercise periods to June 2028.

Cardinal Infrastructure (NASDAQ: CDNL, ~$657M assets) reported Q2 2026 record revenue of $226.9M (+114% YoY, +64% organic) and announced acquisition of Atlanta-based Allied Paving Contractors for ~$120M ($62M cash + $58M stock, 6-month lock-up). Allied generates $108M annual revenue at 20.3% adjusted EBITDA margin; transaction priced at 5.5x adjusted EBITDA. Company raised full-year 2026 revenue guidance to $880–$900M (midpoint +$210M vs. prior guide) and adjusted EBITDA margin guidance to 16–18%. Backlog reached record $866M (+35% YoY). However, Q2 adjusted EBITDA margin fell to 12.4% from 18.6% YoY due to subcontractor/equipment costs in developing markets and weather disruptions; management expects recovery in H2.

Middleby completed separation of Food Processing business on July 6, 2026, launching Midera as independent company. Q2 2026 continuing operations (excl. Food Processing) showed net sales of $631M (+8.3% organic), adjusted EBITDA of $163M (25.8% margin), and adjusted EPS of $1.74. Company repurchased 3.8M shares YTD (7.8% of outstanding) and raised FY 2026 revenue guidance to +6–8% organic growth with $2.48–2.53B sales guidance and $6.73–6.89 adjusted EPS.

Xtant Medical reported Q2 2026 revenue of $23.0M vs. $35.4M in Q2 2025, a 35% decline driven by the December 2025 sale of Coflex/CoFix assets to Companion Spine and cessation of high-margin license revenue. The company acquired exclusive U.S. commercial rights to Dilon Technologies' HEMOBLAST Bellows hemostasis product for $5.0M exclusivity fee and hired ~20 Dilon salespeople. Net loss was $9.4M (vs. +$3.6M net income in Q2 2025); adjusted EBITDA fell to -$2.7M from +$6.9M. Cash declined to $9.9M; full-year guidance reduced to $99–$103M from $101–$105M.

DPC Holdings (NYSE: DPC), a precision casting manufacturer, reported Q2 2026 revenue of $269M (+34% YoY) and adjusted EBITDA of $48M (+33% YoY). The company raised full-year 2026 guidance to $1,000M–$1,040M revenue and $182M–$187M adjusted EBITDA. Key developments: IPO and private placements (net proceeds $1,009M) repaid the $878M Shareholder PIK Loan and eliminated net debt to $118M adjusted net cash position; signed a fourth strategic OEM partnership committing to build a new superalloy facility in Alabama; Moody's upgraded credit to Ba2 with positive outlook (July 28, 2026). GAAP net loss widened to ($131M) due to $129.5M management incentive plan accrual, IPO costs, and share-based compensation, but adjusted net income improved to $6M.

Hemab completed an IPO in May 2026 raising $317.2M net proceeds, bringing total cash to $457.5M (260% of total assets of $175.3M). The company advanced three clinical programs: sutacimig (Phase 3 initiation planned H2 2026 for Glanzmann thrombasthenia with FDA endorsement), HMB-002 (demonstrated ≥2.4-fold VWF/FVIII increase in Phase 1/2), and unveiled HMB-003 (novel plasmin inhibitor for heavy menstrual bleeding, first-in-human studies planned H2 2026). Q2 2026 R&D expenses were $20.3M (vs. $12.9M prior year); net loss was $24.2M ($0.80/share on 30.1M shares) for the quarter.

Chicago Atlantic REFI reported Q2 2026 net income of $7.5M ($0.34/share, diluted), distributable earnings of $9.3M ($0.43/share), and $59.2M gross originations. On July 9, 2026, REFI issued 4,306,754 shares (16.8% dilution) to Koach Capital Funds at $14.53/share for $62.5M of second lien notes secured by 32 retail cannabis properties. The company remains on track to merge with affiliated BDC LIEN in Q4 2026 (NAV-for-NAV exchange; pro-forma REFI shareholders ~50.5% ownership post-close). Portfolio: $453.1M outstanding principal, 26 borrowers, 15.8% gross yield, 46.0% LTEV, 1.2x real estate coverage.

Upstream Bio (NASDAQ: UPB) reported Q2 2026 results with cash and investments of $261.3M (56% of market cap) funding operations through 2027. The company remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027 following completed FDA End-of-Phase 2 interactions. Completed enrollment in Phase 2 COPD trial (481 participants; data expected H2 2027) and reported positive Phase 2 data showing ~80% of patients achieved clinically meaningful nasal polyp improvements with quarterly dosing.

Aura Biosciences completed enrollment of its 108-patient Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding the target and remaining on track for topline data in H2 2027 under FDA Special Protocol Assessment. The company is strategically deprioritizing its non-muscle invasive bladder cancer (NMIBC) program despite encouraging interim data (81% objective response rate), and is implementing a 20% workforce reduction (~$2.9–3.2M restructuring charge) to align resources with ocular oncology focus. Cash runway extended to 1H 2029 with $323.8M in liquid assets as of June 30, 2026. Three C-suite executives departed; three new experienced executives appointed (COO, Chief Regulatory Officer, Chief People Officer).

Beyond Meat's board implemented a 1-for-30 reverse stock split effective August 13, 2026, approved by shareholders on November 19, 2025. The split reduces authorized shares from 3 billion to 100 million and is designed to restore the stock price above Nasdaq's minimum bid requirement. Proportionate adjustments apply to convertible notes, warrants, and equity awards; shareholder ownership percentages remain unchanged.

CVRx announced August 11, 2026, that Chief Revenue Officer Robert John is departing immediately. Paul Verrastro, an internal senior advisor with 30+ years of medical device experience and 5+ years at CVRx (former Chief Marketing and Strategy Officer), assumes interim Head of Sales role while the company searches for a permanent successor. CEO Kevin Hykes cited 'revised commercial outlook and need to improve commercial execution' as the reason for the change.